{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:21:48Z","timestamp":1783812108352,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>T lymphoblastic lymphoma\/acute lymphoblastic leukemia (T-LBL\/ALL) is a highly aggressive hematologic malignancy, with particularly poor outcomes for refractory\/relapsed (R\/R) patients. This article reports the efficacy and safety of V-CHG regimen (Venetoclax, cytarabine, homoharringtonine, G-CSF) in the treatment of three R\/R T-LBL\/ALL cases. One 69 years old female patient with T-ALL experienced a twice relapse and achieved morphological complete remission (CR) with one cycle of V-CHG regimen. Another 65 years old female patient with T-LBL progressed to T-ALL after continuous CR for 10 months and failed by two different salvage chemotherapy regimens. She achieved minimal residual disease (MRD) negative CR with a third-line treatment based on V-CHG regimen. The third T-ALL patient was a 26 years old male who resistant to VDCP induction regimen and achieved morphological CR with one cycle of V-CHG regimen, and obtained MRD negative CR after second cycle treatment. All the three patients were well tolerated to the V-CHG regimen. The results of this study indicate that the V-CHG regimen is effective and safe for R\/R T-LBL\/ALL, warranting further application in the future.<\/jats:p>","DOI":"10.1007\/s12672-025-03055-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:40:04Z","timestamp":1751362804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination of venetoclax with CHG regimen in refractory\/relapsed T-lymphoblastic lymphoma\/acute lymphoblastic leukemia: a case series and literature review"],"prefix":"10.1007","volume":"16","author":[{"given":"Mei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"14","key":"3055_CR1","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/bloodadvances.2020001822","volume":"4","author":"E Kroeze","year":"2020","unstructured":"Kroeze E, Loeffen JLC, Poort VM, Meijerink JPP. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv. 2020;4(14):3466\u201373.","journal-title":"Blood Adv"},{"issue":"7","key":"3055_CR2","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00277-024-05692-1","volume":"103","author":"Y Chen","year":"2024","unstructured":"Chen Y, Chen Y, Wu Z, Li J, Huang Y, Peng X, et al. Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes. Ann Hematol. 2024;103(7):2393\u2013404.","journal-title":"Ann Hematol"},{"issue":"10230","key":"3055_CR3","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"19","key":"3055_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903\u201330.","journal-title":"Blood"},{"key":"3055_CR5","doi-asserted-by":"publisher","first-page":"115820","DOI":"10.1016\/j.biopha.2023.115820","volume":"168","author":"M Hu","year":"2023","unstructured":"Hu M, Li W, Zhang Y, Liang C, Tan J, Wang Y. Venetoclax in adult acute myeloid leukemia. Biomed Pharmacother. 2023;168:115820.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"3055_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"3055_CR7","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186\u201391.","journal-title":"Cancer"},{"issue":"3","key":"3055_CR8","first-page":"229","volume":"12","author":"K Tari","year":"2023","unstructured":"Tari K, Nasimian A, Kazi JU, Abroun S. Venetoclax drug increases the apoptosis of T and B acute lymphoblastic leukemia cells by reducing the expression of BCL-2. Int J Mol Cell Med. 2023;12(3):229\u201341.","journal-title":"Int J Mol Cell Med"},{"issue":"25","key":"3055_CR9","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated Inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738\u201347.","journal-title":"Blood"},{"issue":"3","key":"3055_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, et al. Network-based systems Pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2(3):284\u201399.","journal-title":"Nat Cancer"},{"issue":"9","key":"3055_CR11","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074\u201387.","journal-title":"Cancer Discov"},{"issue":"4","key":"3055_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-Cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"3055_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ejh.14015","volume":"111","author":"J Canaani","year":"2023","unstructured":"Canaani J, Frisch A, Pollyea DA, Schwartz M, Aumann S, Ganzel C, et al. Venetoclax-based salvage therapy for adult patients with relapsed\/refractory acute lymphoblastic leukemia. Eur J Haematol. 2023;111(3):365\u201372.","journal-title":"Eur J Haematol"},{"issue":"6","key":"3055_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440\u201353.","journal-title":"Cancer Discov"},{"issue":"7","key":"3055_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/mc.23534","volume":"62","author":"K Zhou","year":"2023","unstructured":"Zhou K, Gong D, He C, Xiao M, Zhang M, Huang W. Targeted therapy using larotrectinib and venetoclax for the relapsed\/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion. Mol Carcinog. 2023;62(7):899\u2013906.","journal-title":"Mol Carcinog"},{"issue":"24","key":"3055_CR16","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.3390\/cancers14246142","volume":"14","author":"RJ Summers","year":"2022","unstructured":"Summers RJ, Jain J, Vasileiadi E, Smith B, Chimenti ML, Yeung TY, et al. Therapeutic targeting of MERTK and BCL-2 in T-Cell and early T-Precursor acute lymphoblastic leukemia. Cancers (Basel). 2022;14(24):6142.","journal-title":"Cancers (Basel)"},{"key":"3055_CR17","doi-asserted-by":"crossref","unstructured":"La Starza R, Camb\u00f2 B, Pierini A, Bornhauser B, Montanaro A, Bourquin JP et al. Venetoclax and bortezomib in relapsed\/refractory early T-Cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2019;3:PO.19.00172.","DOI":"10.1200\/PO.19.00172"},{"issue":"13","key":"3055_CR18","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL, Zou JY, Qiao M, Yin J, Shen XD, Qiu QC, et al. Venetoclax combined with Azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62(13):3300\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3055_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00277-021-04530-y","volume":"101","author":"J Kong","year":"2022","unstructured":"Kong J, Chen N, Li M, Zhang J, Wu X, Zong L, et al. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Ann Hematol. 2022;101(3):697\u20139.","journal-title":"Ann Hematol"},{"key":"3055_CR20","doi-asserted-by":"crossref","unstructured":"Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A et al. First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2018;2:PO.18.00127.","DOI":"10.1200\/PO.18.00127"},{"issue":"5","key":"3055_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MPH.0000000000002672","volume":"45","author":"P Borah","year":"2023","unstructured":"Borah P, Dayal N, Pathak S, Naithani R. Short-course venetoclax with standard chemotherapy is effective in early T-cell precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2023;45(5):271\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"3055_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, et al. A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv. 2024;8(4):909\u201315.","journal-title":"Blood Adv"},{"issue":"1","key":"3055_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers14010150","volume":"14","author":"A Gibson","year":"2021","unstructured":"Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, et al. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers (Basel). 2021;14(1):150.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3055_CR24","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00277-023-05231-4","volume":"102","author":"S Yi\u011fit Kaya","year":"2023","unstructured":"Yi\u011fit Kaya S, Bektas S, Askin AE, Bal\u0131k Ayd\u0131n B, Mutlu YG, Sevindik \u00d6G. Pegaspargase, venetoclax, and nelarabine: a successful Bridge to allogeneic hematopoietic stem cell transplantation in a relapsed\/refractory T-cell acute lymphoblastic leukemia patient. Ann Hematol. 2023;102(6):1599\u2013600.","journal-title":"Ann Hematol"},{"issue":"4","key":"3055_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12185-023-03623-w","volume":"118","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Jiang S, Tang Y, Zhao L. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023;118(4):483\u20138.","journal-title":"Int J Hematol"},{"issue":"5","key":"3055_CR26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.18487","volume":"199","author":"S Wei","year":"2022","unstructured":"Wei S, Gu R, Song Y, Yan Z, Hu Y, Lin D, et al. Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients. Br J Haematol. 2022;199(5):772\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"3055_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40001-024-01856-x","volume":"29","author":"S Khatua","year":"2024","unstructured":"Khatua S, Nandi S, Nag A, Sen S, Chakraborty N, Naskar A, et al. Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications. Eur J Med Res. 2024;29(1):269.","journal-title":"Eur J Med Res"},{"issue":"6","key":"3055_CR28","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY, et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-\u03baB repressing factor. Proc Natl Acad Sci U S A. 2019;116(6):2220\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3055_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.clml.2013.03.017","volume":"13","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J. Homoharringtonine\/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013;13(5):530\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3055_CR30","doi-asserted-by":"crossref","unstructured":"Suo S, Zhao D, Li F, Zhang Y, Rodriguez-Rodriguez S, Nguyen LXTT et al. Homoharringtonine inhibits the NOTCH\/MYC pathway and exhibits anti-tumor effects in T-cell acute lymphoblastic leukemia. Blood. 2024;144(12):1343\u20137.","DOI":"10.1182\/blood.2023023400"},{"key":"3055_CR31","doi-asserted-by":"crossref","unstructured":"Suo S, Sun S, Nguyen LXT, Qian J, Li F, Zhao D et al. Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed. Med. 2024;5(12):1510\u20131524.e4.","DOI":"10.1016\/j.medj.2024.07.018"},{"issue":"1","key":"3055_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood.2023020276","volume":"143","author":"N Leblay","year":"2024","unstructured":"Leblay N, Ahn S, Tilmont R, Poorebrahim M, Maity R, Lee H, et al. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood. 2024;143(1):42\u201356.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03055-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:40:06Z","timestamp":1751362806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03055-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethical Committee of First Hospital of Tsinghua University and conducted in accordance with the Declaration of Helsinki. Informed consent to participate was obtained from the patients in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients for the publication of the data in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"1202"}}